Proteomic Analysis of the Human Anterior Pituitary Gland

Yelamanchi, Soujanya D.; Tyagi, Ankur; Mohanty,; Dutta, Pinaki; Korbonits, Márta; Chavan, Sandip; Advani, Jayshree; Madugundu, Anil K.; Dey, Gourav; Datta, Keshava K.; Rajyalakshmi, M; Sahasrabuddhe, Nandini A.; Chaturvedi, Abhishek; Kumar, Amit; Das, Apabrita Ayan; Ghosh, Dhiman; Jogdand, Gajendra M.; Nair, Haritha H.; Saini, Keshav; Panchal, Manoj; Sarvaiya, Mansi Ashwinsinh; Mohanraj, Soundappan S.; Sengupta, Nabonita; Saxena, Priti; Subramani, Pradeep Annamalai; Kumar, Pradeep; Akkali, Rakhil; Reshma, S; Santhosh, Ramachandran Sarojini; Rastogi, Sangita; Kumar, Sanjay; Ghosh, Susanta Kumar; Irlapati, Vamshi K.; Srinivasan, Anand; Radotra, Bishan Das; Mathur, Premendu P.; Wong, G. William; Satishchandra, Parthasarathy; Chatterjee, Aditi; Gowda, Harsha; Bhansali, Anil; Pandey, Akhilesh; Shankar, Susarla Krishna; Mahadevan, Anita; Prasad, T. S. Keshava

doi:10.1089/omi.2018.0160

Cited by 12 publications

(8 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, a total of 6076 proteins identified from human NFPA tissues with TMT-based quantitative proteomics in this study (Supplemental Table 1) were compared to a total of 2175 proteins identified from human anterior pituitary gland with SDS-PAGE-LC-MS/MS and LC-LC-MS/MS ( Supplemental Table 12) (69). A total of 1933 proteins were identified in both NFPAs and anterior pituitary gland, 242 proteins were only identified in anterior pituitary gland but not in NFPAs, 4143 proteins were only identified in NFPAs but not in anterior pituitary gland.…”

Section: Discussionmentioning

confidence: 99%

Quantitative Analysis of Proteome in Non-functional Pituitary Adenomas: Clinical Relevance and Potential Benefits for the Patients

Cheng

Wang

et al. 2019

Front. Endocrinol.

View full text Add to dashboard Cite

Background: Non-functional pituitary adenoma (NFPA) is a common tumor that occurs in the pituitary gland, and generally without any symptoms at its early stage and without clinical elevation of hormones, which is commonly diagnosed when it grows up to compress its surrounding tissues and organs. Currently, the pathogenesis of NFPA has not been clarified yet. It is necessary to investigate molecular alterations in NFPA, and identify reliable biomarkers and drug therapeutic targets for effective treatments.Methods: Tandem mass tags (TMT)-based quantitative proteomics was used to identify and quantify proteins in NFPAs. GO and KEGG enrichment analyses were used to analyze the identified proteins. Differentially expressed genes (DEGs) between NFPA and control tissues were obtained from GEO datasets. These two sets of protein and gene data were analyzed to obtain overlapped molecules (genes; proteins), followed by further GO and KEGG pathway analyses of these overlapped molecules, and molecular network analysis to obtain the hub molecules with Cytoscape. Two hub molecules (SRC and AKT1) were verified with Western blotting.Results: Totally 6076 proteins in NFPA tissues were identified, and 3598 DEGs between NFPA and control tissues were identified from GEO database. Overlapping analysis of 6076 proteins and 3598 DEGs obtained 1088 overlapped molecules (DEGs; proteins). KEGG pathway analysis of 6076 proteins obtained 114 statistically significant pathways, including endocytosis, and spliceosome signaling pathways. KEGG pathway analysis of 1088 overlapped molecules obtained 52 statistically significant pathways, including focal adhesion, cGMP-PKG pathway, and platelet activation signaling pathways. These pathways play important roles in cell energy supply, adhesion, and maintenance of the tumor microenvironment. According to the association degree in Cytoscape, ten hub molecules (DEGs; proteins) were identified, including GAPDH, ALB, ACACA, SRC, ENO2, CALM1, POTEE, HSPA8, DECR1, and AKT1. Western-blotting analysis confirmed the upregulated expressions of SRC and PTMScan experiment confirmed the increased levels of pAKT1, in NFPAs compared to controls.Cheng et al. Non-functional Pituitary Adenoma Proteomic ProfilingConclusions: This study established the large-scale quantitative protein profiling of NFPA tissue proteome. It offers a basis for subsequent in-depth proteomics analysis of NFPAs, and insight into the molecular mechanism of NFPAs. It also provided the basic data to discover reliable biomarkers and therapeutic targets for NFPA patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Quantitative Analysis of Proteome in Non-functional Pituitary Adenomas: Clinical Relevance and Potential Benefits for the Patients

Cheng

Wang

et al. 2019

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…High-resolution Fourier transform mass spectrometry is another promising novel technique which has identified 105 novel proteins in the normal anterior pituitary compared with previous high-throughput proteomic-based studies ( 327 ). Using this approach may also identify new candidate proteins and/or pathways driving pituitary tumorigenesis.…”

Section: Epigenetic Mechanisms Of Tumorigenesismentioning

confidence: 99%

Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms

Nadhamuni

Korbonits

2020

Endocrine Reviews

Self Cite

View full text Add to dashboard Cite

Substantial advances have been made recently in the pathobiology of pituitary tumors. Similar to many other endocrine tumors, over the last few years we have recognized the role of germline and somatic mutations in a number of syndromic or non-syndromic conditions with pituitary tumor predisposition. These include the identification of novel germline variants in patients with familial or simplex pituitary tumors and establishment of novel somatic variants identified through next generation sequencing. Advanced techniques have allowed the exploration of epigenetic mechanisms mediated through DNA methylation, histone modifications and non-coding RNAs, such as microRNA, long noncoding RNAs and circular RNAs. These mechanisms can influence tumor formation, growth and invasion. While genetic and epigenetic mechanisms often disrupt similar pathways, such as cell cycle regulation, in pituitary tumors there is little overlap between genes altered by germline, somatic and epigenetic mechanisms. The interplay between these complex mechanisms driving tumorigenesis are best studied in the emerging multi-omics studies. Here, we summarize insights from the recent developments in the regulation of pituitary tumorigenesis.

show abstract

“…Region‐specific data of the human anterior pituitary would more accurately clarify any alterations of secreted proteins, and would facilitate investigations on their physiological role. A systematic proteomic profile of human anterior pituitary glands identified 480 proteins with secretory potential and 187 N‐terminally acetylated proteins with high‐resolution Fourier transform MS (Yelamanchi et al, 2018). Accurate clarification of the role of the human anterior pituitary gland would accelerate precision medicine and biomedical research.…”

Section: Current Status Of Multiomics Studies Of Pasmentioning

confidence: 99%

The use of mass spectrometry in a proteome‐centered multiomics study of human pituitary adenomas

Desiderio

Zhan

2021

Mass Spectrometry Reviews

View full text Add to dashboard Cite

A pituitary adenoma (PA) is a common intracranial neoplasm, and is a complex, chronic, and whole-body disease with multicausing factors, multiprocesses, and multiconsequences. It is very difficult to clarify molecular mechanism and treat PAs from the single-factor strategy model. The rapid development of multiomics and systems biology changed the paradigms from a traditional single-factor strategy to a multiparameter systematic strategy for effective management of PAs.A series of molecular alterations at the genome, transcriptome, proteome, peptidome, metabolome, and radiome levels are involved in pituitary tumorigenesis, and mutually associate into a complex molecular network system. Also, the center of multiomics is moving from structural genomics to phenomics, including proteomics and metabolomics in the medical sciences. Mass spectrometry (MS) has been extensively used in phenomics studies of human PAs to clarify molecular mechanisms, and to discover biomarkers and therapeutic targets/drugs. MS-based

show abstract

Proteomic Analysis of the Human Anterior Pituitary Gland

Cited by 12 publications

References 54 publications

Quantitative Analysis of Proteome in Non-functional Pituitary Adenomas: Clinical Relevance and Potential Benefits for the Patients

Quantitative Analysis of Proteome in Non-functional Pituitary Adenomas: Clinical Relevance and Potential Benefits for the Patients

Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms

The use of mass spectrometry in a proteome‐centered multiomics study of human pituitary adenomas

Contact Info

Product

Resources

About